Analytical Data
-
基因名
C20orf35
- Application
-
别名
Dysbindin domain-containing Protein 2. Casein kinase-1 binding Protein. CK1BP. HSMNP1
-
种属
Human
-
表达系统
E. coli
-
标签
GST-tag at N-terminal
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q9BQY9
-
表达区间
1-156aa
-
氨基酸序列
MAGQFRSYVWDPLLILSQIVLMQTVYYGSLGLWLALVDGLVRSSPSLDQMFDAEILGFSTPPGRLSMMSFILNALTCALGLLYFIRRGKQCLDFTVTVHFFHLLGCWFYSSRFPSALTWWLVQAVCIALMAVIGEYLCMRTELKEIPLNSAPKSNV
-
分子量
44 KDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
C20orf35, also known as ROR1, is a gene located on chromosome 20 that has garnered attention due to its unique expression pattern and potential implications in various diseases, particularly in cancer. Initially identified in embryonic development, C20orf35 is typically downregulated in adult tissues, suggesting a role in normal physiological processes. However, its aberrant expression has been observed in several malignancies, including chronic lymphocytic leukemia and breast cancer, indicating its potential role as a tumor-associated antigen. Research into the recombinant protein of C20orf35 focuses on understanding its structural and functional properties, which may elucidate its involvement in tumorigenesis. The recombinant C20orf35 protein can serve as a valuable tool for developing targeted therapies and vaccines, as it may facilitate the design of immunological strategies that exploit the immune system’s ability to recognize and attack cancer cells expressing this protein. Furthermore, studying its interactions with other cellular pathways can provide insights into the mechanisms that drive cancer progression. Overall, the investigation of C20orf35 recombinant protein represents a promising frontier in cancer research, aiming to uncover novel therapeutic approaches and improve outcomes for patients.
